<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04167228</url>
  </required_header>
  <id_info>
    <org_study_id>FCO-CAV-2018-01</org_study_id>
    <nct_id>NCT04167228</nct_id>
  </id_info>
  <brief_title>Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria</brief_title>
  <acronym>CAVICOR</acronym>
  <official_title>Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maimónides Biomedical Research Institute of Córdoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimónides Biomedical Research Institute of Córdoba</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with infections caused by carbapenem-resistant enterobacteria treated with CAZ-AVI&#xD;
      versus patients treated with BAT are compared. The BAT group includes fosfomycin,&#xD;
      tigecycline, gentamicin, meropenem and colistin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Carbapenem-resistant enterobacteria (CRE) are a public health problem. The morbidity and&#xD;
      mortality of patients with invasive infections due to CRE are high. The best treatment is&#xD;
      unknown, however, combination therapy with at least 2 active drugs is often recommended for&#xD;
      high-risk patients, and monotherapy is probably not inferior to this in low-risk patients.&#xD;
&#xD;
      Ceftazidime-avibactam is active against many CRE, and in some countries it has been&#xD;
      prescribed under compassionate use programs for these infections; It has recently been&#xD;
      approved by the FDA and the EMA for specific indications. Recent data suggest that&#xD;
      ceftazidime-avibactam may be superior for the treatment of infections caused by sensitive&#xD;
      CRE, rather than traditional regimens that often include colistin, usually combined with&#xD;
      other drugs. However, these studies include a low number of patients and are subject to&#xD;
      important biases.&#xD;
&#xD;
      Additionally, the development of resistance to this drug during / after treatment has been&#xD;
      described and is worrying.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Actual">May 5, 2021</completion_date>
  <primary_completion_date type="Actual">July 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>30-day mortality rate</measure>
    <time_frame>At day 30 after the start of the treatment</time_frame>
    <description>To describe the 30-day mortality rate in the caz-avi group and in the group with the best available therapy of patients with infections caused by carbapenem-resistant enterobacteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical response on day 21</measure>
    <time_frame>At day 21 after the start of the treatment</time_frame>
    <description>To describe the clinical response on day 21 of the caz-avi group and in the group with the best available therapy of patients with infections caused by carbapenem-resistant enterobacteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiological response</measure>
    <time_frame>At day 30 after the start of the treatment</time_frame>
    <description>Microbiological response in the Test-of-cure, categorized as eradication, microbiological failure or uncertain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day mortality rate in the group of patients with caz-avi in monotherapy and in the group with combined therapy with caz-avi</measure>
    <time_frame>At day 30 after the start of the treatment</time_frame>
    <description>Describe the 30-day mortality rate in the group of patients with caz-avi in monotherapy and in the group with combined therapy with caz-avi, who present with infections caused by carbapenem-resistant enterobacteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors associated with the development of resistance to ceftazidime-avibactam during treatmen</measure>
    <time_frame>At day 30 after the start of the treatment</time_frame>
    <description>Describe the rates and risk factors associated with the development of resistance to ceftazidime-avibactam (MIC&gt; 8 microg / mL) during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay after infection</measure>
    <time_frame>At day 30 after the start of the treatment</time_frame>
    <description>Number of days elapsed from the end of antibiotic treatment until discharge and duration of ICU stay if appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of antibiotic treatment during the episode</measure>
    <time_frame>At day 30 after the start of the treatment</time_frame>
    <description>Number of days of antibiotic treatment during the episode</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence</measure>
    <time_frame>At day 30 after the start of the treatment</time_frame>
    <description>Reappearance of the infection according to the same criteria and by the same microorganism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation of the treatment</measure>
    <time_frame>At day 30 after the start of the treatment</time_frame>
    <description>Number of adverse reactions related to therapy</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">348</enrollment>
  <condition>Carbapenem-Resistant Enterobacteriaceae Infection</condition>
  <arm_group>
    <arm_group_label>CRE infected patients treated with ceftazidime-avibactam</arm_group_label>
    <description>Patients with infections caused by carbapenem resistant enterobacteria treated with ceftazidime-avibactam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRE infected patients treated with best available treatment</arm_group_label>
    <description>Patients with infections caused by carbapenem resistant enterobacteria treated with the best available treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftazidime-Avibactam</intervention_name>
    <description>Patients with complicated urinary tract infections, nosocomial pneumonia (including pneumonia associated with ventilation), complicated intra-abdominal infections or bacteremia (if the focus of infection is any of the above, the patient should be included in both groups) due to CRE, treated &gt; 2 days with ceftazidime-avibactam.</description>
    <arm_group_label>CRE infected patients treated with ceftazidime-avibactam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Best Available Therapy</intervention_name>
    <description>Patients with complicated urinary tract infections, nosocomial pneumonia (including pneumonia associated with ventilation), complicated intra-abdominal infections or bacteremia (if the focus of infection is any of the above, the patient should be included in both groups) due to CRE, treated &gt; 2 days with the best available treatment other than ceftazidime-avibactam.</description>
    <arm_group_label>CRE infected patients treated with best available treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with infections caused by carbapenem resistant enterobacteria&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with complicated urinary tract infections, nosocomial pneumonia (including&#xD;
             pneumonia associated with ventilation), complicated intra-abdominal infections or&#xD;
             bacteremia (if the focus of infection is any of the above, the patient should be&#xD;
             included in both groups) due to CRE, treated &gt; 2 days with ceftazidime-avibactam.&#xD;
             Patients with bacteremia can be included in one of the other cohorts if the focus of&#xD;
             the infection is the urinary tract, respiratory tract or an intra-abdominal infection&#xD;
             and they meet the appropriate criteria (see below). The retrospective design of this&#xD;
             study has been carried out to avoid the induction of the prescription of&#xD;
             ceftazidime-avibactam in each center. For this, patients will be included at the end&#xD;
             of the period of evaluation of the primary objective (crude mortality at day 30). If&#xD;
             more than one patient can be used as a control, the one with the closest admission&#xD;
             date will be chosen.&#xD;
&#xD;
        Control: local historical cohort - Patients treated with ceftazidime-avibactam will be&#xD;
        compared with patients treated with BAT. Because after approval of the use of&#xD;
        ceftazidime-avibactam, BAT could be used less frequently to treat this type of infection,&#xD;
        patients treated with BAT from January 1, 2014 will be included. These patients will be&#xD;
        matched by hospital, type of hospital. infection (urinary tract vs others) and INCREMENT&#xD;
        score.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The infection is considered polymicrobial according to the standard microbiological&#xD;
             interpretation of the crop results (except for complicated intra-abdominal infections,&#xD;
             in which case, polymicrobial infections are allowed).&#xD;
&#xD;
          -  Patients with infections caused by CRE without susceptibility to&#xD;
             ceftazidime-avibactam.&#xD;
&#xD;
          -  The patient is participating in a clinical trial that involves active treatment for&#xD;
             infections.&#xD;
&#xD;
          -  Patients with cardiopulmonary no resuscitation order or with a life expectancy &lt; 30&#xD;
             days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan José Castón Osorio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Reina Sofía</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Gran Canaria &quot;Dr. Negrín&quot;</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <state>Canary Islands</state>
        <zip>35019</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <state>Coruña</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Álvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36211</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcántara</name>
      <address>
        <city>Cáceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 14, 2019</study_first_submitted>
  <study_first_submitted_qc>November 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ceftazidime / avibactam</keyword>
  <keyword>carbapenem resistant enterobacteria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Enterobacteriaceae Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftazidime</mesh_term>
    <mesh_term>Avibactam</mesh_term>
    <mesh_term>Avibactam, ceftazidime drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The information collected will be of public access by request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After the trial results are public.</ipd_time_frame>
    <ipd_access_criteria>By request to uicec@imibic.org</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

